WALTHAM, Mass. — February 6, 2026 — Leads & Copy — Pulmovant, a Roivant company (Nasdaq: ROIV), has completed enrollment in its Phase 2 PHocus clinical trial, evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The clinical-stage biotechnology company, committed to transforming the lives of patients with pulmonary diseases, announced that enrollment was completed in under 12 months from the first patient dosed.
Topline results from the study are expected in the second half of calendar year 2026.
Mosliciguat is a potential first-in-class, once-daily, inhaled sGC activator with a differentiated mechanism of action designed to deliver targeted pulmonary vasodilation with limited systemic side effects for the treatment of PH-ILD, a progressive and life-threatening condition.
The Phase 2 PHocus clinical study (NCT06635850) is a randomized, double-blind, placebo-controlled, global trial assessing the safety and efficacy of mosliciguat in approximately 120 adult participants with PH-ILD.
Mosliciguat is also being evaluated in the Phase 2 PHactor clinical study (NCT07333183), an open-label trial evaluating the tolerability and safety of inhaled mosliciguat in combination with inhaled treprostinil in participants with PH-ILD.
Drew Fromkin, Chief Executive Officer of Pulmovant, said that completing enrollment of the PHocus study in less than one year from first patient dosed underscores the strong demand for new therapeutic options for patients suffering from PH-ILD.
According to Fromkin, people living with PH-ILD have limited treatment options as current therapies are often poorly tolerated and require multiple doses per day, contributing to a high treatment burden.
Pulmonary hypertension (PH) is characterized by high blood pressure in the blood vessels of the lungs. This elevated pressure forces the heart to work harder to pump blood through the lungs, leading to symptoms such as shortness of breath, fatigue, chest pain, and dizziness.
The World Health Organization (WHO) has classified PH into five groups based on their underlying causes, symptoms, and treatment approaches. Group 3 PH is a subtype of PH that arises from lung diseases, such as interstitial lung disease (ILD).
ILD describes a large group of diseases that cause progressive damage to the lungs, making it difficult for patients to breathe. Up to 200,000 patients across the U.S. and Europe are living with PH-ILD, a subset of Group 3 PH, and have limited or no approved treatment options.
Mosliciguat targets sGC, a key enzyme in the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP) signaling pathway that catalyzes cGMP production. Elevated cGMP levels are known to promote vasodilation, contribute to anti-fibrotic effects, reduce inflammation and apoptosis and reverse vascular remodeling.
In the Phase 1b ATMOS study of mosliciguat, a single dose of inhaled mosliciguat in PH patients was well tolerated and led to clinically meaningful, mean peak reduction in pulmonary vascular resistance (PVR) of up to 38%.
“This milestone is a remarkable achievement and a testament to the dedication of the study participants and investigators as well as the Pulmovant team’s execution. We are deeply grateful for their collaboration in advancing mosliciguat’s development, which brings us closer to a potentially differentiated treatment for patients with PH-ILD and may also benefit patients with other conditions associated with pulmonary hypertension and pulmonary disorders more broadly,” Fromkin said.
Pulmovant’s first investigational candidate, mosliciguat, is designed to provide a novel, once-daily, inhaled treatment option for patients with pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD).
Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease.
Roivant creates subsidiaries or “Vants” to develop and commercialize medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Source: Pulmovant
